Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeutics is expanding into a second autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback